DK2447275T3 - Methods and reagents for the treatment of age-related macular degeneration - Google Patents

Methods and reagents for the treatment of age-related macular degeneration Download PDF

Info

Publication number
DK2447275T3
DK2447275T3 DK12152177.7T DK12152177T DK2447275T3 DK 2447275 T3 DK2447275 T3 DK 2447275T3 DK 12152177 T DK12152177 T DK 12152177T DK 2447275 T3 DK2447275 T3 DK 2447275T3
Authority
DK
Denmark
Prior art keywords
cfhr1
ser
antibody
cfhr3
glu
Prior art date
Application number
DK12152177.7T
Other languages
Danish (da)
English (en)
Inventor
Gregory S Hageman
Original Assignee
Univ Iowa Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38924245&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2447275(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Iowa Res Found filed Critical Univ Iowa Res Found
Application granted granted Critical
Publication of DK2447275T3 publication Critical patent/DK2447275T3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/112Disease subtyping, staging or classification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/136Screening for pharmacological compounds
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/172Haplotypes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/32Cardiovascular disorders
    • G01N2800/329Diseases of the aorta or its branches, e.g. aneurysms, aortic dissection
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/14Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333Saccharide [e.g., DNA, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
DK12152177.7T 2006-07-13 2007-07-13 Methods and reagents for the treatment of age-related macular degeneration DK2447275T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83101806P 2006-07-13 2006-07-13
US84007306P 2006-08-23 2006-08-23
EP07812932A EP2046807B1 (en) 2006-07-13 2007-07-13 Methods and reagents for treatment and diagnosis of vascular disorders and age-related macular degeneration

Publications (1)

Publication Number Publication Date
DK2447275T3 true DK2447275T3 (en) 2015-06-29

Family

ID=38924245

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12152177.7T DK2447275T3 (en) 2006-07-13 2007-07-13 Methods and reagents for the treatment of age-related macular degeneration

Country Status (11)

Country Link
US (4) US7867727B2 (https=)
EP (3) EP2479284B1 (https=)
JP (1) JP5431151B2 (https=)
AT (1) ATE551350T1 (https=)
AU (1) AU2007272335B2 (https=)
CA (1) CA2659392A1 (https=)
DK (1) DK2447275T3 (https=)
IL (1) IL196319A0 (https=)
NZ (1) NZ574046A (https=)
SG (1) SG173371A1 (https=)
WO (1) WO2008008986A2 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2357254A1 (en) * 2005-02-14 2011-08-17 University of Iowa Research Foundation Methods and reagents for treatment and diagnosis of age-related macular degeneration
US20080146501A1 (en) * 2006-02-13 2008-06-19 University Of Iowa Research Foundation Protective complement proteins and age-related macular degeneration
US8012683B2 (en) 2006-02-13 2011-09-06 University Of Iowa Research Foundation Variants in complement regulatory genes predict age-related macular degeneration
AU2007277125B2 (en) * 2006-07-26 2013-08-01 Yale University Diagnosis and treatment of age related macular degeneration
EP2217720A4 (en) * 2007-11-01 2010-12-08 Univ Iowa Res Found RNA LOCUS ANALYSIS TO ASSESS THE STUNNING FOR AMD AND MPGNII
US20090186370A1 (en) * 2008-01-18 2009-07-23 Ogle Matthew F Diagnostic biomarkers for vascular aneurysm
DE102008049136B4 (de) * 2008-09-26 2012-10-25 Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e.V. Neue Regulatoren des angeborenen Immunsystems
JP2012533562A (ja) * 2009-07-16 2012-12-27 グラクソ ウェルカム マニュファクチュアリング ピーティーイー リミテッド 治療法
US20120190578A1 (en) * 2009-08-06 2012-07-26 Washington University Plasma Complement Components as Expression Markers for Age-Related Macular Degeneration and Related Phenotypes
EP2478377A2 (de) * 2009-09-14 2012-07-25 Mosaiques Diagnostics And Therapeutics AG Polypeptidmarker zur diagnostik und beurteilung vaskulärer erkrankungen
JP5706612B2 (ja) * 2009-12-28 2015-04-22 学校法人 埼玉医科大学 加齢黄斑変性症易罹患性の判定マーカー並びに判定方法及び判定キット
US20120202708A1 (en) * 2010-10-14 2012-08-09 Sequenom, Inc. Complement factor h copy number variants found in the rca locus
US9598733B2 (en) * 2011-02-17 2017-03-21 The Trustees Of Columbia University In The City Of New York Methods for identifying subjects with a genetic risk for developing IgA nephropathy
CA2834676A1 (en) * 2011-04-29 2012-11-01 University Of Utah Research Foundation Methods of predicting the development of complement-mediated disease
JP2013064616A (ja) * 2011-09-15 2013-04-11 Osaka Univ 高度動脈硬化を発症している可能性を検出する方法およびその利用
WO2013150132A2 (de) * 2012-04-05 2013-10-10 Mosaiques Diagnostics And Therapeutics Ag Polypeptidmarker zur diagnostik und beurteilung von schlaganfällen
GB201301632D0 (en) * 2013-01-30 2013-03-13 Imp Innovations Complement System
EP2962106A1 (en) * 2013-02-26 2016-01-06 Roche Diagnostics GmbH Agents, kits and methods for complement factor h-related protein 1 detection
US10202647B2 (en) 2013-04-12 2019-02-12 The Trustees Of Columbia University In The City Of New York Mutations in DSTYK cause dominant urinary tract malformations
WO2014194213A1 (en) * 2013-05-30 2014-12-04 University Of Iowa Research Foundation Specific complement proteins and efficacy of antibody therapy
US10155983B2 (en) 2014-03-31 2018-12-18 Machaon Diagnostics, Inc. Method of diagnosis of complement-mediated thrombotic microangiopathies
JP7199966B2 (ja) 2015-12-23 2023-01-06 ソルボンヌ ウニベルシテ CD11b/CD18に対するCFHの結合を阻害する薬剤、およびその使用
CA3023802C (en) 2016-05-10 2025-02-04 Inserm (Institut De La Sante Et De La Recherche Medicale) ACTIVATING AGENTS OF THE DIFFERENTIATION CLUSTER 47 FOR USE IN THE TREATMENT OF INFLAMMATION
GB201800620D0 (en) 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide
EP3791180A1 (en) * 2018-05-10 2021-03-17 The University Of Manchester Methods for assessing macular degeneration
EP3824095A4 (en) 2018-07-20 2022-04-20 University of Utah Research Foundation GENE THERAPY FOR MACULATE GENERATION
DE102018120016B4 (de) 2018-08-16 2020-09-03 Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e.V. -Hans-Knöll-Institut- Modulatoren der Funktion von Faktor H-verwandtem Protein 1 und deren Verwendungen in der Kontrolle von Entzündung
WO2020180147A2 (ko) * 2019-03-07 2020-09-10 (주)레티마크 나이관련 황반변성 진단용 복합 마커 및 이의 용도
WO2020210724A1 (en) 2019-04-10 2020-10-15 University Of Utah Research Foundation Htra1 modulation for treatment of amd
CA3158517A1 (en) * 2019-10-22 2021-04-29 Applied Genetic Technologies Corporation Adeno-associated virus (aav)vectors for the treatment of age-related macular degeneration and other ocular diseases and disorders
WO2022058447A1 (en) * 2020-09-16 2022-03-24 The University Of Manchester Complementome assay

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
NO870613L (no) 1986-03-05 1987-09-07 Molecular Diagnostics Inc Deteksjon av mikroorganismer i en prŸve inneholdende nukleinsyre.
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US6893625B1 (en) 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
US5037746A (en) 1986-12-03 1991-08-06 University Patents, Inc. RNA ribozyme polymerases, and methods
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
ATE243754T1 (de) 1987-05-21 2003-07-15 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung
JP2897959B2 (ja) 1988-05-20 1999-05-31 エフ.ホフマン―ラ ロシュ アクチェンゲゼルシャフト 固定化された配列特異的プローブ
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5180818A (en) 1990-03-21 1993-01-19 The University Of Colorado Foundation, Inc. Site specific cleavage of single-stranded dna
US20020032313A1 (en) * 1991-03-29 2002-03-14 Genentech, Inc. Vascular endothelial cell growth factor antagonists
EP1413587A2 (en) 1991-05-03 2004-04-28 Washington University Modified complement system regulator
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5474796A (en) 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
ATE198358T1 (de) 1992-04-27 2001-01-15 Dartmouth College Detektion von gensequenzen in biologischen flüssigkeiten
EP0681482B1 (en) 1993-01-22 2005-12-07 University Research Corporation Localization of therapeutic agents
US5667969A (en) 1993-11-12 1997-09-16 University Research Corporation Alteration of sequence of a deleterious target molecule by ribozyme catalyzed trans-splicing
US5578832A (en) 1994-09-02 1996-11-26 Affymetrix, Inc. Method and apparatus for imaging a sample on a device
US5556752A (en) 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
US6706471B1 (en) 1996-01-24 2004-03-16 Third Wave Technologies, Inc. Detection of nucleic acid sequences by invader-directed cleavage
US6299895B1 (en) 1997-03-24 2001-10-09 Neurotech S.A. Device and method for treating ophthalmic diseases
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
GB9710475D0 (en) 1997-05-21 1997-07-16 Zeneca Ltd Gene silencing
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
NZ507093A (en) 1998-04-08 2003-08-29 Commw Scient Ind Res Org Methods and means for reducing the phenotypic expression of a nucleic acid of interest in a plant
EP2314700A1 (en) 1999-01-28 2011-04-27 Medical College of Georgia Research Institute, Inc Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA
AU3704500A (en) 1999-02-19 2001-01-22 University Of Iowa Research Foundation, The Diagnostics and therapeutics for arterial wall disruptive disorders
US20020102581A1 (en) 1999-02-19 2002-08-01 Hageman Gregory S. Diagnostics and therapeutics for ocular disorders
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
US7011952B2 (en) 2000-02-22 2006-03-14 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration-related disorders
PT1309726E (pt) 2000-03-30 2010-03-08 Whitehead Biomedical Inst Mediadores de interferência por rna específicos de sequência de rna
AU2001261103B2 (en) 2000-04-29 2007-08-23 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration-related disorders
US6632606B1 (en) 2000-06-12 2003-10-14 Aclara Biosciences, Inc. Methods for single nucleotide polymorphism detection
US20040259247A1 (en) 2000-12-01 2004-12-23 Thomas Tuschl Rna interference mediating small rna molecules
AUPR604101A0 (en) 2001-06-29 2001-07-26 Unisearch Limited Aptamers
WO2003016470A2 (en) 2001-08-10 2003-02-27 University Of Virginia Patent Foundation Enhancing the efficacy of immunotherapies by supplementing with complement
CN102618644A (zh) * 2004-11-18 2012-08-01 耶鲁大学 治疗眼病的方法和组合物
EP2357254A1 (en) 2005-02-14 2011-08-17 University of Iowa Research Foundation Methods and reagents for treatment and diagnosis of age-related macular degeneration
EP2570491A1 (en) 2005-06-08 2013-03-20 University of Pittsburgh of the Commonwealth System of Higher Education Susceptibility genes for age-related maculopathy (ARM) on chromosome 10q26
KR20080065657A (ko) 2005-10-11 2008-07-14 예일 유니버시티 황반 변성 관련 유전자
US20080255000A1 (en) 2005-11-02 2008-10-16 Dogulu Cigdem F Method Evolved for Recognition and Testing of Age Related Macular Degeneration (Mert-Armd)
US8012683B2 (en) 2006-02-13 2011-09-06 University Of Iowa Research Foundation Variants in complement regulatory genes predict age-related macular degeneration
US20080146501A1 (en) 2006-02-13 2008-06-19 University Of Iowa Research Foundation Protective complement proteins and age-related macular degeneration
GB0611606D0 (en) * 2006-06-13 2006-07-19 Univ Belfast Protection against and treatment of age related macular degeneration

Also Published As

Publication number Publication date
EP2046807A4 (en) 2009-10-28
HK1126223A1 (en) 2009-08-28
EP2479284B1 (en) 2017-09-20
EP2046807A2 (en) 2009-04-15
IL196319A0 (en) 2009-09-22
JP2009544280A (ja) 2009-12-17
CA2659392A1 (en) 2008-01-17
EP2046807B1 (en) 2012-03-28
US20080152659A1 (en) 2008-06-26
EP2479284A2 (en) 2012-07-25
US7867727B2 (en) 2011-01-11
AU2007272335A1 (en) 2008-01-17
US20120040884A1 (en) 2012-02-16
EP2447275B1 (en) 2015-04-01
EP2479284A3 (en) 2012-08-08
US20180371547A1 (en) 2018-12-27
NZ574046A (en) 2012-09-28
WO2008008986A2 (en) 2008-01-17
SG173371A1 (en) 2011-08-29
AU2007272335B2 (en) 2014-03-27
ATE551350T1 (de) 2012-04-15
US20150050646A1 (en) 2015-02-19
WO2008008986A3 (en) 2008-10-23
EP2447275A1 (en) 2012-05-02
HK1168360A1 (en) 2012-12-28
JP5431151B2 (ja) 2014-03-05

Similar Documents

Publication Publication Date Title
DK2447275T3 (en) Methods and reagents for the treatment of age-related macular degeneration
CA2704809A1 (en) Rca locus analysis to assess susceptibility to amd and mpgnii
JP2002330758A (ja) 化学化合物
US20050059067A1 (en) Chemical compounds
JP2010508838A (ja) TNF−α遮断薬に対する治療応答性の予測方法
WO2007067896A1 (en) Method for determining vasoreactivity
HK1168360B (en) Methods and reagents for treatment of age-related macular degeneration
JP4242590B2 (ja) 慢性関節リウマチの疾患感受性遺伝子、及びその利用
AU2016204271B2 (en) Methods and reagents for the treatment and diagnosis of vascular disorders and age-related macular degeneration
US6316188B1 (en) Histamine-N-methyltransferase variants associated with histaminergic disease
US8530167B2 (en) Diagnostic and therapeutic uses of GNPTAB, GNPTG, and NAGPA in stuttering
HK1126223B (en) Methods and reagents for treatment and diagnosis of vascular disorders and age-related macular degeneration
US7745121B2 (en) Polymorphism in the macrophage migration inhibitory factor (MIF) gene as marker for prostate cancer
WO2003035691A1 (en) Apolipoprotein a-i mutation useful for diagnosis and treatment of cardiovascular diseases
AU2013202401A1 (en) Methods and reagents for the treatment and diagnosis of vascular disorders and age-related macular degeneration
Hageman et al. Complement factor H for diagnosis of age-related macular degeneration
HK1172070A (en) Methods and reagents for treatment and diagnosis of vascular disorders and age-related macular degeneration
WO2002054939A2 (en) Methods and compositions for diagnosing and treating neuropsychiatric disorders such as schizophrenia
WO2001073116A2 (en) Method for determining osteoporosis susceptibility and/or low bone density and reagents therefor
Schultz et al. Copyright© 2003 Oxford University Press
WO2005071104A1 (en) Assay for bipolar affective disorder
WO2006136791A1 (en) Polymorphisms and haplotypes in p2x7 gene and their use in determining susceptibility for atherosclerosis-mediated diseases